Mizuho Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its price objective hoisted by research analysts at Mizuho from $13.00 to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential upside of 3.52% from the company’s previous close.

MD has been the topic of several other reports. Truist Financial increased their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Jefferies Financial Group increased their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, UBS Group upped their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Performance

Shares of NYSE:MD opened at $14.49 on Tuesday. The firm’s 50 day simple moving average is $12.77 and its 200-day simple moving average is $9.96. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The firm has a market cap of $1.24 billion, a PE ratio of -4.74, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period last year, the business posted $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities analysts predict that Pediatrix Medical Group will post 1.25 EPS for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock valued at $751,277 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC boosted its holdings in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth about $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at about $33,000. Quarry LP increased its stake in shares of Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.